Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00611793 · ClinicalTrials.gov registry record · Phase 1
PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies
A Phase 1 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT00611793 is a Phase 1 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 50 participants.
The verdict
NCT00611793, a Phase 1 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
PTK787/ZK222584 is an orally active inhibitor of VEGF-R tyrosine kinases. Bevacizumab is an intravenous humanized monoclonal antibody directed against vascular endothelial growth factor. By binding to VEGF, bevacizumab blocks VEGF-A receptor binding. Due to the different mechanisms of action and the non-overlapping toxicity profiles of the two agents, it is hoped that a combination regimen incorporating both compounds will produce increased activity without enhanced toxicity.
Interventions
- DRUG PTK787/ZK222584 and Bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2004-10 |
| Est. Completion | 2009-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00611793
The ClinicalTrials.gov registry entry for NCT00611793 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PTK787/ZK222584 and Bevacizumab is the first listed.
NCT00611793 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00611793 about?
NCT00611793 is a clinical study titled "PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies". PTK787/ZK222584 is an orally active inhibitor of VEGF-R tyrosine kinases. Bevacizumab is an intravenous humanized monoclonal antibody directed against vascular endothelial growth factor. By binding to VEGF, bevacizumab blocks VEGF-A receptor binding. Due to the different mechanisms of action and the...
What is the current status of trial NCT00611793?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2004-10. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00611793?
The interventions under investigation include: PTK787/ZK222584 and Bevacizumab (DRUG).
Who is sponsoring clinical trial NCT00611793?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.